HideChilds = False
SystemName = Homepage

Bioverativ – Science matters. Because patients matter.

Science matters.
Because patients matter.

Learn more

Science that redefines what’s possible

Learn how Bioverativ is working to change the treatment paradigm in hemophilia A.

Learn more

Expanding access around the world

We committed, with Sobi, to donate up to 1 billion IUs of factor therapy to the developing world. Already, more than 15,000 people with hemophilia have been treated.

Learn more

Bioverativ (a Sanofi company) in the news

Monday, December 3, 2018 1:30 PM

BIVV001 Phase 1/2a Data Presented at ASH Underscore Potential for Once Weekly Dosing with Sustained High Factor Levels in Hemophilia A

Read more